Trial Profile

CLARA: A Phase 1/2 Multi-center, Randomized, Double-Masked, Prospective, Parallel-Arm Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Neltependocel (Primary) ; Protein kinase inhibitors
Indications Corneal disorders
Focus Therapeutic Use
Acronyms CLARA
Sponsors Aurion Biotech

Most Recent Events

26 Mar 2025 According to an Aurion Biotech Media Release, results of this study support the advancement of AURN001 into Phase 3 development
18 Dec 2024 According to an Aurion Biotech Media Release, full results from the CLARA trial to be presented at future medical conferences.
18 Dec 2024 Primary endpoint (BCVA - 15-letter improvement (3-line gain)) has been met, according to an Aurion Biotech Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com